Comparison between Two Regimens of Art in Human Immunodeficiency Virus Patients at Tertiary Care Art Centre Jabalpur: A Prospective Observational Study
Objective: The objective of the study was to assess the effectiveness of two regimens (Tenofovir + Lamivudine + Efavirenz
[TLE] and Zidovudine + Lamivudine + Nevirapine [ZLN]) on the basis of CD4
count changes among human immunodeficiency
virus (HIV) patients along with occurrence of adverse drug reactions (ADRs) by these regimens.
Materials and Methods: A prospective observational study with a sample size of 200, divided equally into two groups of 100
each jointly conducted in the Tertiary Care ART Centre Jabalpur, from April 2016 to June 2017. Group A contains TLE regimen,
and Group B contains ZLN regimen. Various ADRs were observed in both the groups.
Results: Most of the patients were male (124) in our study with a maximum incidence of HIV found among 21–40 years of age
group. The average increase in the CD4 count was significant only in GroupA (<0.05). 83% and 93% patients of GroupsA and B,
show a total of 137 and 165 ADRs, respectively. Group A shows major central nervous system and gastrointestinal tract and
Group B shows mainly dermatology and hematological type of ADRs. Using Modified Hartwig and Siegel severity assessment
scale, we found that in Group A, ADR was mild to moderate in nature while in Group B, ADR was mainly moderate in nature.
Conclusion: It was concluded that Group A containing TLE regimen was more effective as their CD4 count was significantly
increase after a follow-up of 6-month treatment with least ADR and the patients who develop ADR was mainly mild in nature.
Available from: https://www.en.wikipedia.org/wiki /HIV/AIDS_in_the_
Democratic_Republic_of_the_Congo. [Last assessed on 2018 Jun 01].
2. WHO. HIV/AIDS-World Health Organization. Available from: http://www.
who.int/features/qa/71/en/. [Last assessed on 2018 Jun 02].
3. Robbins SL, Cotran RS. The diseases of immunity. Pathology Basis of
Disease. 9th ed. New York: Elsevier; 2015. p. 243.
4. UNAIDS. AIDSinfo. Country Factsheets India; 2016. Available from:
http://www.aidsinfo.unaids.org. [Last assessed on 2018 Jun 14].
5. UNAIDS. GLOBAL AIDS UPDATE; 2016. Available from: http://www.
en.pdf. [Last assessed on 2018 Jun 21].
6. Shah RR, Masatkar V, Bohra S, Malek N, Ghose G, Pandya HP. Has HAART
won heart of HIV/AIDS patients? World J Pharm Life Sci 2017;3:184-98.
7. Bhuvana KB, Hema NG, Sangeetha. A prospective observational study of
adverse drug reactions to antiretroviral therapy: Type and risk factors in a
tertiary care teaching hospital. Int J Basic Clin Pharmacol 2014;3:380-4.
8. Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment inreporting adverse drug reactions. Ame J Health Syst Pharm 1992;49:2229-32.
9. Sehgal R, Gupta MC, Ghalaut PS. Adverse event monitoring of antiretroviral
drugs- A pharmacovigilance perspective. Int J Pharmacol Res 2017;7:65-70.
10. Rajput JS, Mathur MK, Chaurasia AK, Singh S, Tiwari A. The effect of
nevirapine vs efavirenz containing regimens on clinical outcomes among
HIV patients on ART: A comparative study. Int J Adv Med 2017;4:768-71.
11. Krishnan CR, Sajeeth CI. A comparative study of antiretroviral therapy
induced CD4 T-cell changes among HIV infected patients. Int. Res J Pharm
12. Jain A, Lihite RJ, Lahkar M, Baruah SK. A study on adverse drug reactionsto first-line antiretroviral therapy in HIV infected patients at a tertiary care
hospital in Northeast India. HIV AIDS Rev 2016;15:131-5.
13. Lorío M, Colasanti J, Moreira S, Gutierrez G, Quant C. Adverse drug
reactions to antiretroviral therapy in HIV-infected patients at the largest
public hospital in Nicaragua. J Int Assoc Provid AIDS Care 2014;13:466-70.
14. Sharma A, Vora R, Modi M, Sharma A, Marfatia Y. Adverse effects of
antiretroviral treatment. Indian J Dermatol Venereol Leprol 2008;74:234-7.
15. Anwikar SR, Bandekar MS, Smrati B, Pazare AP, Tatke PA, Kshirsagar NA.
HAART induced adverse drug reactions: A retrospective analysis at a tertiary
referral health care center in India. Int J Risk Saf Med 2011;23:163-9.